0701 GMT - Australia-based biotech company CSL, which collects plasma in the U.S. and manufactures many plasma-based products at plants in Europe, would likely need to raise prices by between 4% to 5.1% to offset Trump's planned tariffs on pharmaceuticals, say Jefferies analysts. While it isn't clear exactly how the Trump pharmaceutical tariffs will work, the good news for CSL is that over time it may be able to move plasma product manufacturing from high tariff locations in Europe to lower tariff areas like Australia, say David Stanton and Vanessa Thomson. This will put it in a slightly better position than its major European competitors. But in general, "plasma companies may see difficulties transferring complex, expensive operations at plants that can take years to build," they add. CSL shares ended 5% lower. (mike.cherney@wsj.com; @Mike_Cherney)
(END) Dow Jones Newswires
April 09, 2025 03:01 ET (07:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。